Over the projected period, the high incidence of cancer is anticipated to drive growth in the global array market (life science and biotechnology instruments). For instance, the American Cancer Society predicts that there will be 606,880 cancer deaths and 1,762,450 new cancer cases in the United States in 2019.
Additionally, throughout the course of the forecast period, it is anticipated that rising genetic testing use would fuel growth of the global array market (life science and biotechnology instruments). For instance, in April 2020, paediatric lysosomal storage disorder patients in the United States and Canada were given access to free genetic testing thanks to a partnership between Axovant Gene Therapies and Invitae Corporation, a provider of advanced medical genetics.
According to estimates, the global market for Life Science And Biotechnology Instruments would be worth US$4,899.9 Mn in 2020 and US$12,892.5 Mn by the end of 2027
Key Companies in the Array Industry:
Illumina Inc.:
1. .Illumina offers products and services for the analysis of genetic material for use in clinical and life science lab settings. Over 90% of the company's income comes from the sale of sequencing equipment, supplies, and services. Humans and other large species can have their entire genomes sequenced thanks to Illumina's high-throughput technology. Created in 1998. United States headquarters. Illumina Acquires GRAIL to Speed Up Access for Patients to a Life-Saving Multi-Cancer Early-Detection Test
Roche Diagnostics Inc.:
2. Swiss biopharmaceutical and diagnostic business Roche. A number of oncology medicines from the company's acquired partner Genentech are among its top-selling pharmaceutical items, and the 2008 acquisition of Ventana strengthened its diagnostics division. Built in 1896. Base of operations in Switzerland. Recent acquisitions include GenMark Diagnostics (March 2021) and Good Therapeutics (Sep 2022).
Bio-Rad Laboratories:
3. With its headquarters in Hercules, California, Bio-Rad Laboratories creates, produces, and sells goods and services for the clinical diagnostics and life sciences industries. Bio-Rad produces, markets, and maintains test systems and specialised quality controls for clinical laboratories in the diagnostics sector (53% of revenue). Built in 1952. United States headquarters.
